Document Detail


Sevoflurane in intraoperative and postoperative cardiac surgery patients. Our experience in intensive care unit with sevoflurane sedation.
MedLine Citation:
PMID:  23228318     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Recently, many studies have shown a decrease in myocardial damage in patients undergoing coronary artery bypass surgery where the anesthetic agent used was sevoflurane compared with propofol. The basis for this protective effect of the myocardium occurs through the mechanisms of preconditioning and postconditioning of halogenated agents. Both relate to the benefit of prior or subsequent administration of the drug (halogenated anesthetic agent) to the harmful stimulus for myocardial cells. The two mechanisms have similar effector mechanisms. The intraoperative administration of sevoflurane is common in anesthetic practice, but the continuation of the administration in the first postoperative hours is made possible by the AnaConDa ® device (ACD; Sedana Medical AB, Uppsala, Sweden) designed for halogenated sedation of patients admitted to intensive care units (ICU). This device has proven useful to facilitate the treatment of pathological conditions. The object of our review is to determine if there are beneficial effects to extending exposure to halogenated agents in the immediate post-operative period . In the post-operative phase, the pathological myocardium is in a reperfusion process in the coronary microcirculation and expression of certain receptors and chemical mediators can reduce potential injury secondary to reperfusion of previously hibernating and/or stunned tissue.
Authors:
Guerrero Orriach; Ramirez Aliaga; Galan Ortega; Rubio Navarro; Navarro Arce; Cruz Mañas
Related Documents :
195508 - Pathophysiology of myocardial infarction.
11293648 - The myocardial na+/h+ exchanger: a potential therapeutic target for the prevention of m...
10722688 - Urocortin protects against ischemic and reperfusion injury via a mapk-dependent pathway.
2221118 - Role of iron on membrane phospholipid breakdown in ischemic-reperfused rat heart.
1831068 - Left ventricular diastolic function in athletes and borderline hypertensives with mild ...
19878648 - Myocardial release of fkbp12 and increased production of fkbp12.6 in ischemia and reper...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-04
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  Curr. Pharm. Des.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-11     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Hospital Virgen de la Victoria Campus Universitario Teatinos C.P. 29010 Malaga Spain. guerreroorriach@terra.es.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Corticosteroids for the inflammatory response to cardiopulmonary bypass: an update.
Next Document:  Dexmedetomidine: A review of its use for the management of pain, agitation, and delirium in the inte...